---
document_datetime: 2023-09-21 17:12:42
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/agenerase-epar-all-authorised-presentations_en.pdf
document_name: agenerase-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.9173426
conversion_datetime: 2025-12-23 01:46:29.049606
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| EU Number       | Invented name   | Strength   | Pharmaceutical form   | Route of administration   | Packaging                | Content           | Package size                   |
|-----------------|-----------------|------------|-----------------------|---------------------------|--------------------------|-------------------|--------------------------------|
| EU/1/00/148/001 | Agenerase       | 50 mg      | Capsule, soft         | Oral use                  | bottle (HDPE)            |                   | 480                            |
| EU/1/00/148/002 | Agenerase       | 150 mg     | Capsule, soft         | Oral use                  | bottle (HDPE)            |                   | 240                            |
| EU/1/00/148/003 | Agenerase       | 150 mg     | Capsule, soft         | Oral use                  | bottle (HDPE)            |                   | 2 bottles of 240               |
| EU/1/00/148/004 | Agenerase       | 15 mg/ml   | Oral solution         | Oral use                  | authorised bottle (HDPE) | 240 ml (15 mg/ml) | 1 bottle + 20 ml measuring cup |

Medicinal product no longer authorised 1/1